Tough times for Tecen­triq as NICE once again slaps down Roche's im­munother­a­py — slight ben­e­fit not worth price

The UK drug-pric­ing watch­dog has again nixed Roche and its can­cer im­munother­a­py Tecen­triq.

The Na­tion­al In­sti­tute for Health and Care Ex­cel­lence’s lat­est fil­ing is for ex­ten­sive-stage small cell lung can­cer pa­tients. The reg­u­la­tor de­ter­mined that al­though Tecen­triq ap­peared to im­prove pa­tient sur­vival and qual­i­ty of life in clin­i­cal tri­als, that da­ta was un­cer­tain and based on pa­tients who were dis­sim­i­lar to the av­er­age NHS pa­tient. The ben­e­fits Roche had shown were not worth the drug’s on av­er­age £32,800 (rough­ly $43,300) price, NICE said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.